As Alepidea amatymbica is commonly used and accepted as medicinal plant in South Africa for various indications, the scientific basis of its anecdotally described, putative anti-HIV properties was investigated. To this aim, we used an accelerated extraction-purification approach; extracts and therein sub-fractions of A. amatymbica were assessed in a cell-based assay targeting the replication of prototypic CXCR4-tropic (NL4-3) or CCR5-tropic (NL-AD87) HIV-1 strains.
Introduction
The human immunodeficiency virus (HIV) is globally currently one of the most deleterious pathogens causing disease and death associated with profound immunosuppression (1, 2) . It is estimated that more than 20 million people with HIV/AIDS have died since the first AIDS cases were described in 1981. Sub-Saharan Africa is the hardest-hit region in the world. Approximately 22.5 million people in Sub-Saharan Africa live with HIV. Furthermore, in some parts of Sub-Saharan Africa, the seroprevalence of HIV in the general population is still at alarmingly high levels of up to 26% (3) .
The pandemic in these areas has reached levels where the economic development of entire societies is threatened or stopped. Current prevention strategies are still inadequate to stop the rapid spread of the epidemic and the search for safe, affordable treatment for HIV thus remains a major challenge and key towards controlling the disease.
South Africa with its rich plant biodiversity with close to 24,500 plants species represents an enormous potential source of antiviral compounds. However, until today only few isolated studies have investigated the anti-HIV properties of South African medicinal plants (1, 4) . In response to this shortcoming, a collaborative research programme was initiated at the Council for Scientific and Industrial Research (CSIR) in South Africa that aimed at screening plant extracts and at identifying new anti-HIV drug leads. CSIR is approached on a regular basis by knowledge holders and Traditional Health Practitioners to undertake research on their plant based medicines. As one outcome from this effort the present report evaluates the activity of aqueous extracts of Alepidea amatymbica against the HIV virus as the plant was brought to the CSIR by a Traditional Health Practitioner to evaluate its beneficial properties to HIV infected patients (CSIR, confidential documentation on file).
A. amatymbica belongs to the family Apiaceae, and the approximately 28 species in the genus are predominantly found in Africa (5) and are endemic to grassland areas of eastern and southern Africa (5, 6) . Rhizomes and roots of A. amatymbica are used in South Africa as a traditional medicine (7, 8) .
A. amatymbica is known under the Zulu name 'iKhataso' and is used for the treatment of colds and chest complaints (8) as well as for asthma, influenza, diarrhoea and abdominal cramps, sore throat and rheumatism (7) . As the plant is used for treating diseases that affect the patients' "immune system" it was added to our screening system for investigating in more detail its potential use in HIV therapy.
Previous phytochemical investigation of rhizomes and roots of the plant have resulted in the isolation of several diterpenoid kaurene derivatives (9, 10) , and more recently phenolic acids have been identified (11) .
Materials and Methods

Plant material
All plant species were identified in Trenmore, South Africa (GPS 27º 59´ 54 E, 311º 8´ 27 S), and the whole plants (leaves, stems, and roots) were collected. A voucher specimen (No PRE577495.0) was deposited and identified at the South African National Biodiversity Institute (SANBI).
Extraction
Aerial parts and roots of the plant were cut into small pieces and dried in an oven at 30-60 ºC for 48 hours. Dried material was ground to a coarse powder using a hammer mill and stored at ambient temperature prior to extraction. The powdered plant material (500 g) was extracted with purified water. The aqueous extract was filtered and concentrated by freeze-drying and stored at -20ºC prior to analysis.
General experimental procedures
Analytical grade solvents for extraction and HPLC grade solvents for chromatography were purchased from Romil Pure Chemistry (Cambridge, UK). HPLC grade water was obtained from a TKA Ultra Pure water purification system (Niederelbert, Germany). Formic acid (98.0-100.0%) was purchased from Sigma Aldrich (South Africa). Reference materials rosmarinic acid (>98.0% purity) and caffeic acid (>98.0% HPLC purity) were purchased from Tocris Bioscience (R&D Systems Europe, UK) and Sigma Aldrich (Basel, Switzerland), respectively.
Semi-preparative purification
The extract was fractionated using an Agilent 1200 semi preparative HPLC system consisting of auto sampler, high pressure mixing pump, column oven, and diode array detector (DAD). Semi-preparative purification was carried out using an Atlantis Preparative T3 column (C18, 5µm, 10 X 250mm, min, a plateau at 90% aqueous acetonitrile; 15-16 min, increase to 100% acetonitrile; 16-17.8 min, 100% acetonitrile. Column was developed at a flow rate of 5 mL/min; absorption spectrum (190-700 nm) was recorded in real-time. Five hundred µL of sample at a concentration of 25 mg/mL in water were injected and fractions were collected every 0.2 min in a 96-well microtitre plate.
Residual solvent was evaporated from the collection 96-well microtitre plates using a GeneVac EZ-2
Plus evaporator at 40ºC with pre-installed "HPLC fractions" vacuum settings. Four injections per plate were completed and this process was repeated 3 times thus generating 3 identical microtitre plates.
UPLC-Mass spectrometry analysis
UPLC-MS data were obtained with a Waters Acquity UPLC system connected in series to a Waters photodiode array (PDA) detector as well as aSYNAPT G1 HDMS QTOF (4KDa) mass spectrometer.
The system was controlled through MassLynx v4.1 SCN639. UPLC separation was performed using an Acquity HSS T3 column (C18, 1.8µm, 150 x 2.1mm, Waters) at 40°C. Chromatographic solvents were ultra-pure water containing 0.1% v/v) formic acid (Solvent A) and UPLC grade acetonitrile Fractions of interest were analysed by electrospray ionisation-quadrupole time-of-flight mass spectrometry (ESI-QTOF MS) using a scanning range of 100 to 1200 Da. The SYNAPT G1 mass spectrometer was used in V-optics and operated in electrospray ionisation mode. The mass spectrometer was operated in negative mode with a capillary voltage of 2.5 kV, the sampling cone at 30 V and the extraction cone at 5 V. The scan time was 0.1 seconds covering the 100 to 1200 Dalton mass range. The source temperature was 120 °C and the desolvation temperature was set at 400 °C .
Nitrogen gas was used as the nebulisation gas at a flow rate of 800 L/h. The trap collision energy was set at 6V while the transfer optics collision energy was set to 4V. The Synapt mass spectrometer was calibrated using a formic acid solution in acetonitrile to obtain a mass accuracy below 5 mDa for the scan range of 100 to 1200 Da. A Lockmass interface was used to maintain mass accuracy and utilised a 50 pg/mL leucine encephalin solution infused at 10 uL/min.
Drug susceptibility testing
The anti viral properties of the extracts were assessed in a cell-based replicative assay. The assay was carried out exactly as described in (12) Data were processed and analysed as described elsewhere (12) .
Results
In an effort to identify new antiviral lead compounds of natural origin active against HIV, the aqueous extract of A. amatymbica was screened in a cell-based infection assay designed to detect inhibitors blocking any step of the viral life cycle. Two HIV-1 laboratory strains differing by their receptor tropism namely, NL4-3 for CXCR4-usage and NL-AD87 for CCR5-usage, were used for the assessment. The EC 50 values of the aqueous extracts were determined as 22 µg/mL against the HIV-1 strain NL4-3 and 85 µg/mL against NL-AD87. The extract was found to be non-toxic as judged by observing cell density and morphology.
In order to optimise the process of identifying active compounds, an accelerated purification and identification route was adopted (Figure 1 ). An HPLC fractionation protocol was established and a total of 150 mg of extract was separated using reverse phase semi-preparative HPLC (see materials and methods). A maximum of 4 cycles of HPLC fractionation was performed per 96-well microtitre plate with the generation of three replicate plates. The first plate was used to identify fractions inhibiting HIV replication; the second plate was analysed using UPLC QTOF, and the third plate was stored as a reference plate. This approach speeds up the development time as correlation to bioactive fractions can be made within a much shorter timeframe than with a standard sequential method.
Selection of active fractions was based on two criteria: a threshold of more than 50% inhibition of viral replication for dilution 1:20 ( Figure 2 ) and greater than 20% for the dilution 1:200 (data not shown) in addition to a lack of overt cellular toxicity. Based on these criteria, fractions B11 to D4
were considered the most active ones and were selected for further analysis. In order to ascertain if the fractions contained the same or a common compound, the base peak intensity (BPI) chromatogram (negative mode) of fractions B11, C6 and C12 were analysed in more detail (Figure 3 ). rosmarinic acid, which has previously been reported to occur in A. amatymbica [11] . To definitely ascertain that the compound is identical to rosmarinic acid, the pure standard was obtained from a commercial source. The retention time and mass fragmentation of the rosmarinic acid standard, when analysed by UPLC QTOF confirmed it is the major compound in the most active fractions. The activity of the pure compound against HIV replication was then assessed as described above. EC 50 values were 30µM and 47µM against NL4-3 and NL-AD87, respectively ( Figure 5 ).
In addition, as rosmarinic acid was only found to be a minor component of fraction C4, the latter was analysed in greater detail. Using the exact same methodology as described above, the major component of this fraction was identified as caffeic acid (not shown). However, when tested in our bioassays, the commercial standard of caffeic acid only displayed a strong cytotoxic activity (not shown).
Discussion
The accelerated approach for identification of potentially new anti-HIV leads from complex plant extracts using our semi-preparative HPLC fractionation procedure was proven to be successful. This was demonstrated through the dereplication of aqueous extract of A. amatymbica which has led to the identification of rosmarinic acid, a compound already known to possess a weak inhibitory activity for HIV. This physico-chemical process was achieved within a period of 2 months including the time for biological screening. It has been reported (15) that the classical bioassay-guided approach for the dereplication of extracts typically takes much longer time (several months to even years) while often the realization that the active compounds are published or patented happens at a much later stage resulting in wastage of time and resources. The accelerated approach allows natural product drug discovery scientists to make a go/no go decision on the further development of the active compounds much earlier in the research development programme. In addition, the combination of medium-throughput screening methodology for activity using 96-well microtitre plates is essential for the success of this accelerated approach.
Caffeic acid, a key intermediate in lignin biosynthesis found in numerous plants, has been described as a weak inhibitor of HIV replication in vitro (16) . However, in our bioassay this compound proved to be only cytotoxic. Some of its natural derivatives such as caffeic acid phenethyl ester are more potent inhibitors and target the integrase enzyme of the virus (17) . Similarly, rosmarinic acid, which derives from caffeic acid, has a superior anti-HIV activity with higher potency in our assay. This molecule is known to bind in the catalytic core of purified HIV-1 integrase and thereby blocks with equal potency both activities of this enzyme namely, 3'-processing and strand transfer (18) . However, this desired antiviral property is counterbalanced by a poor uptake in vivo (19, 20) and by rapid degradation by gut flora (21) . Therefore, due to these unfavourable properties, rosmarinic acid cannot be considered a suitable candidate for an anti-HIV drug, and for these reasons, the potential efficacy of aqueous extracts of A. amatymbica against AIDS cannot be ascribed to a direct antiviral activity.
On the other hand, but departing from the direct use of a herbal extract for HIV therapy, a medicinal chemistry approach towards simple synthetic modifications of rosmarinic acid could be undertaken with the view not only to render it bioavailable but also to produce more active analogues. Such an approach has been already described for caffeic acid, which has been used as a pharmacophore and modified with the aim to improve its bioactivities (22) (23) (24) .
In 
